

Q1

X



**LANXESS – Conference Call
Q1 2014 results and equity increase to
support re-alignment**

Matthias Zachert, CEO

LANXESS
Energizing Chemistry

Safe harbor statement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

Notice

This publication does not constitute a public offer of securities in Germany. It is not for publication or distribution, directly or indirectly, in or into the United States of America. This publication does not constitute an offer to sell securities, or a solicitation of an offer to buy securities, in the United States of America or in any other jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 'Securities Act'). The securities of Lanxess AG described herein have not been and will not be registered under the Securities Act, or the laws of any State, and may not be offered or sold within the United States of America, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable State laws. Lanxess AG does not intend to register any portion of the offering in the United States of America or conduct a public offering of securities in the United States of America.

This presentation contains certain forward-looking statements, including assumptions, opinions and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

Agenda

- LANXESS' development – a strong and successful basis
- Where we are today / way forward
- Q1 results
- Outlook


LANXESS – a strong and successful history

From a “NewCo” to a chemical brand

- Transformation from an unwanted child into an established chemical player
- Successful development rewarded and reflected externally (first share price @ 15.75€)



Increasing global footprint



Strong business leaderships

- Quality, technology and process leadership in many products across the company
- Strong market positions (#1-4 in most business units)



Good financial strength for most of the years

- Investment grade rating since spin-off
- Strong maturity profile with long term financing



BBB
neg. outlook




Baa2
neg. outlook



BBB
neg. outlook

Strong fundamentals face apparent challenges



Agenda

- LANXESS' development – a strong and successful basis
- Where we are today / way forward
- Q1 results
- Outlook

- S/D balances in the rubber industry mid-term unfavorable

Leading market positions ...

Halo Butyl

- LANXESS globally #2 of 3 established players

Nd-PBR

- LANXESS leading player in quality and technology
- Globally #1 (of total ~7 established players)

SSBR


- Amongst the leading players with high quality

EPDM


- LANXESS globally #1 (ACE technology)



... but investments were made in an up-cycle move



- We have returned to an uncompetitive cost structure




Overhead Costs 2013

- Overhead costs have substantially increased since 2009
- We are at “pre-restructuring levels” of 2005
- Cost structure has become inappropriate for the type of businesses we have
- R&D alone has risen by ~110% since 2007

We have to get back to cost competitive structures again

LANXESS Debt / EBITDA ratio is currently too high



Deterioration is actively addressed by a set of measures:

- Back to capex discipline
- Cost savings program to be initiated
- Portfolio measures to be considered

Committed to our investment grade rating

All references to EBITDA are pre exceptionals; all reference to Debt: Debt = financial debt – cash + pensions + oper. leases
pensions are provisions on balance sheet, operating leases are included with amount of minimum future payments

Rationale: Capital increase of 10% to fund restructuring and to avoid further stretch of balance sheet

Investors participate in improvement trajectory

- Support necessary restructuring measures
- Improve financial position to protect investment grade
- Strengthen future development

Investors buy a business with a solid basis and growth prospects

- Prudent management with strong track-record
- Future growth potential based on
 - Regionally diversified assets to serve long-term growth trends
 - Broad customer and end market base



Capital increase is embedded into further measures to improve performance and to strengthen the balance sheet

“Let’s LANXESS again” - program

Overhead competitiveness

- “Right-size” corporate structures
- Improve decision-making processes

Business unit competitiveness

- Challenge existing structures
- Improve approach to markets / customers

Production competitiveness

- Analyse profitability of sites
- Evaluate mothballings
- Evaluate site closures

Portfolio competitiveness

- Evaluate portfolio options to improve the rubber and balance the company set-up

Former strong LANXESS culture to be re-vitalized



“Advance” HR measures concluded in line with expectations

Agenda

- LANXESS' development – a strong and successful basis
- Where we are today / way forward
- Q1 results
- Outlook

A mixed quarter as expected – “Let’s LANXESS again” kick-off



- Earnings improvement in Advanced Intermediates and Performance Chemicals
- Good volume development in Performance Polymers and Performance Chemicals, however partly comparing to a low base



Intermediates and Chemicals balance ...



- Margin levels in some synthetic rubbers were lower yoy and sequentially (driven by BUs KEL and BTR)
- Butadiene pricing again with regional imbalance (advantage for Asian rubber producers), pointing to challenges in Q2 2014
- Strike in Butyl plant (Antwerp, BE) until end of April leads to idle costs and missed business



... continuing challenges in Polymers






- Capital increase to fund restructuring and strengthen financials
- New “Let’s LANXESS again” program set up to improve performance



Initiating improvements

Q1 2014: Positive volumes, but price levels in Performance Polymers remain subdued

Q1 yoy sales variances		Price	Volume	Currency	Portf.	Total
	Perf. Polymers	-12%	8%	-2%	0%	-6%
	Adv. Intermediates	-4%	2%	-1%	0%	-3%
	Perf. Chemicals	0%	8%	-3%	1%	6%
LANXESS		-7%	7%	-2%	0%	-2%

- Higher volumes are offset by lower prices; some headwind from currency
- Volumes increase in all segments, however partly comparing to a low base


Q1 yoy EBITDA pre bridge [€ m]




- Selling price decline exceeds input cost relief; driven by BUs KEL und BTR
- Others mainly reflects the absence of ramp-up costs
- Strike costs burden is part of operational business

Q1 2014: Emerging market sales decline mainly on account of Performance Polymers

Q1 2014 sales by region [%]



Regional development of sales [€ million]



* Currency and portfolio adjusted

Q1 2014 financial overview: Earnings improvement – however at low levels

[€ m]	Q1 2013	Q1 2014	yoy in %
Sales	2,095	2,043	-2.5%
EBITDA pre except. margin	174 8.3%	205 10.0%	17.8%
EPS	0.30	0.30	0.0%
EPS pre ¹	0.34	0.53	55.9%
Capex ²	93	108	16.1%
[€ m]	31.12.2013	31.03.2014	Δ %
Net financial debt	1,731	1,832	5.8%
Net working capital	1,679	1,880	12.0%
Employees	17,343	17,039	-1.8%

- Sales decline as higher volumes fully offset lower prices, while negative currency effects burden additionally
- EBITDA and margin improve mainly due to the absence of one-time burdens
- EPS increase held back by exceptional items from “Advance” efficiency program
- Net financial debt development driven by seasonal working capital increase
- Headcount reduction mainly due to “Advance” program

¹ Net of exceptionals, using the local tax rate applicable where the expenses were incurred

² Net of capitalized borrowing costs, projects financed by customers and finance lease

Q1 2014: EBITDA increase, but operational performance not satisfactory

[€ m]	Q1 2013	Q1 2014	yoy in %	
Sales	2,095 (100%)	2,043 (100%)	-2%	<ul style="list-style-type: none"> ▪ Sales declined as volumes (+7%) offset prices (-7%) and currency weighs (-2%) ▪ Cost of sales showed a disproportionately large decline due to the absence of prior-year one-time burdens (~€30 m from ramp-up costs in BU BTR and technology change in BU KEL) ▪ “Advance” measures and savings reflected in overhead cost decline ▪ Operational performance burdened by strike
Cost of sales	-1,700 (81%)	-1,626 (80%)	4%	
Selling	-189 (9%)	-186 (9%)	2%	
G&A	-79 (4%)	-74 (4%)	6%	
R&D	-48 (2%)	-45 (2%)	6%	
EBIT	67 (3%)	75 (4%)	12%	
Net Income	25 (1%)	25 (1%)	0%	
EPS	0.30	0.30	0%	
EPS pre ¹	0.34	0.53	56%	
EBITDA	169 (8%)	178 (9%)	5%	
thereof exceptionals	-5 (0%)	-27 (1%)	<-100%	
EBITDA pre exceptionals	174 (8.3%)	205 (10.0%)	18%	

Profitability increase mainly due to absence of one-time effects

¹ Net of exceptionals, using the local tax rate applicable where the expenses were incurred

Performance Polymers: Slight EBITDA improvement


[€ m]	Q1 2013	Q1 2014	Δ
Sales	1,134	1,063	-6.3%
EBIT	52	52	0.0%
Depr. / Amort.	60	56	-6.7%
EBITDA pre exceptionals	112	117	4.5%
Margin	9.9%	11.0%	
Capex*	58	76	31.0%

Q1 comments

- Lower selling prices mainly raw material-driven (e.g. butadiene, ethylene)
- Positive volumes across nearly all BUs
- BUs HPE and HPM show solid EBITDA improvement, whilst BU BTR negatively impacted by strike and BU KEL faces ongoing price pressure
- D&A at lower levels after impairment of BUs KEL and HPE
- Capex increase driven by BU PBR (SG) and BU KEL (CN)



Q1 sales bridge yoy [€ m]



* Net of capitalized borrowing, costs projects financed by customers and finance lease

Advanced Intermediates: Good diversification delivers resilient performance / margins


[€ m]	Q1 2013	Q1 2014	Δ
Sales	433	419	-3.2%
EBIT	54	48	-11.1%
Depr. / Amort.	17	23	35.3%
EBITDA pre exceptionals	71	72	1.4%
Margin	16.4%	17.2%	
Capex*	19	19	0.0%

Q1 comments

- Lower selling prices in line with lower raw material prices (mainly toluene in BU All)
- Higher volumes driven by strong agro business in both BUs
- EBITDA and profitability at high level stemming from good utilization and exposure to diversified customer industries; some currency headwind
- D&A increases from a higher asset base in both business units



Q1 sales bridge yoy [€ m]



* Net of capitalized borrowing costs, projects financed by customers and finance lease

Performance Chemicals: Good contribution from almost all business units


[€ m]	Q1 2013	Q1 2014	Δ
Sales	520	550	5.8%
EBIT	29	38	31.0%
Depr. / Amort.	21	20	-4.8%
EBITDA pre exceptionals	51	68	33.3%
Margin	9.8%	12.4%	
Capex*	19	10	-47.4%

Q1 comments

- Prices remain broadly stable
- Volume increase in all BUs: BU IPG with strongest contribution (good construction business; mild winter in Europe) and BUs RCH and RUC strong, however compared to low base
- Positive EBITDA development across the segment; strong increase from construction-related business and reliable operations in BU LEA (CO₂ supply secured)
- Capex declines mainly as investments in BU LEA are finalized



Q1 sales bridge yoy [€ m]



* Net of capitalized borrowing costs, projects financed by customers and finance lease

Financial metrics stretched but measures initiated

[€ m]	Dec 13	Mar 14
Total assets	6,811	6,998
Equity	1,900	1,892
Equity ratio	28%	27%
Net financial debt	1,731	1,832
Net financial debt/EBITDA pre¹	2.36	2.39
Near cash, cash & cash equivalents	533	528
Pension provisions	943	1,004
ROCE¹	5.8%	6.2%
Net working capital	1,679	1,880
Net working capital/sales¹	20%	23%
DSI (in days) ²	58	60
DSO (in days) ²	48	52

- Net financial debt increased sequentially due to higher working capital
- Cash & cash equivalents available to fund redemption of €500 m bond (7.75% coupon) in April 2014
- Pensions increase mainly due to lower interest rates
- Net working capital increases mainly due to higher receivables (higher sales in Mar'14 vs Dec'13)
- DSI and DSO at moderate levels

¹ Based on last twelve months for EBIT pre, EBITDA pre or sales

² Days of sales in inventories / Days of sales outstanding calculated on quarterly sales

³ Targeted range for net financial debt / EBITDA pre of 1.0x – 1.5x through a normal business cycle

Q1 2014: Working capital increase bites into operating cash-flow

[€ m]	Q1 2013	Q1 2014	
Profit before tax	31	38	<ul style="list-style-type: none"> ▪ Profit before tax on previous year's low level ▪ D&A nearly unchanged as impairments at year-end 2013 offset D&A from new assets ▪ Change of cash taxes due to timing of payments ▪ Changes in other assets and liabilities reflects cash-neutral provision building for "Advance" and personnel costs ▪ Increase in working capital funded by operating cash flow
Depreciation & amortization	102	103	
Gain from sale of assets	0	-1	
Result from investments (using equity method)	0	0	
Financial (gains) losses	25	25	
Cash tax payments/refunds	-34	10	
Changes in other assets and liabilities	1	42	
Operating cash flow before changes in WC	125	217	
Changes in working capital	-285	-208	
Operating cash flow	-160	9	
Investing cash flow	144	-122	
thereof capex*	-93	-108	
Financing cash flow	-19	89	

Negative free cash-flow due to weak business performance

* Net of capitalized borrowing costs, projects financed by customers and finance lease

Agenda

- LANXESS' development – a strong and successful basis
- Where we are today / way forward
- Q1 results
- Outlook

LANXESS' process for improvements started, but results will take time

Macro expectations 2014

- Tire industry (especially Europe) to develop better than 2013 trough, whilst Q1 growth rate will not be maintained throughout the year
- Automotive industry with slightly improved environment in Europe and the US, while Asia/Pacific will continue to show stable growth rates
- Agro chemicals with ongoing good demand
- Construction industry expected to grow more dynamically especially in North America and Asia/Pacific – Europe with improved prospects
- US Dollar expected volatile in 2014; political uncertainties remain a risk

LANXESS expectations 2014

- For Q2 2014 we see EBITDA pre between €220-240 m
- For FY 2014 we expect an improved EBITDA pre in the bandwidth of €770-830 m



LANXESS

Energizing Chemistry



Appendix


Housekeeping items for consideration

Additional financial expectations

- Capex 2014: around previous year's level (2013: €624 m)
- Capex 2015: clearly <€600 m
- Capex 2016: €400-450 m
- D&A 2014: ~€400-420 m
- Reconciliation 2014: ~€190 m
- Annual tax rate:
 - mid-term: In normalized business environment and after completion of efficiency program ~22-25%
 - 2014: tax rate will be higher
- Hedging 2014: ~45% at 1.25 -1.40 USD/EUR
- Hedging 2015: ~20% at 1.25 -1.40 USD/EUR



Q1 2014: EBITDA increase in all segments



Total group sales and EBITDA pre figures include reconciliation

Balance sheet

[€ m]	Jun'13	Dec'13	Mar'14		Jun'13	Dec'13	Mar'14
Non-current assets	3,820	3,592	3,604	Stockholders' equity	2,198	1,900	1,892
Intangible assets	388	323	318	Non-current liabilities	3,097	3,029	2,998
Property, plant & equipment	3,081	2,903	2,910	Pension & post empl. provis.	921	943	1,004
Equity investments	0	12	13	Other provisions	286	258	267
Other investments	14	13	14	Other financial liabilities	1,681	1,649	1,578
Other financial assets	7	11	11	Tax liabilities	35	49	30
Deferred taxes	213	254	268	Other liabilities	103	101	90
Other non-current assets	117	76	70	Deferred taxes	71	29	29
Current assets	3,448	3,219	3,394	Current liabilities	1,973	1,882	2,108
Inventories	1,527	1,299	1,363	Other provisions	366	355	381
Trade accounts receivable	1,212	1,070	1,176	Other financial liabilities	740	668	858
Other financial & current assets	338	317	327	Trade accounts payable	657	690	659
Near cash assets	97	106	123	Tax liabilities	27	21	49
Cash and cash equivalents	274	427	405	Other liabilities	183	148	161
Total assets	7,268	6,811	6,998	Total equity & liabilities	7,268	6,811	6,998

- Receivables and inventories higher due to increasing business activity
- Pensions provisions increase mainly in Germany (interest rate reduction)
- Current liabilities increase due to reclassification of Renminbi bond* (from non-current to current)

* Chinese dim-sum bond (CHN500 m) matures in February 2015

Major projects expected to be on stream after 2014

**2013
(completed)**

BU BTR Butyl (SGP), Q1 2013, new plant 100kt
 BU HPE Chloroprene rubber (GER), H2 2013, debottlenecking +10%
 BU All Dichlorobenzene (GER), Q1 2013, debottlenecking +15%
 BU All Cresols (GER), end of 2013, debottlenecking +20%
 BU LEA Leather chemicals (CHN), H1 2013, up to 50kt
 BU LEA CO₂ plant (ZA), Q4 2013, new plant

2014

BU HPM Polyamide (Belgium), Q3 2014, new plant 90kt
 BU HPM Compounding (BRA), Q2 2014, new plant 20kt
 BU LPT Ion exchange resins (GER), mid 2014, debottlenecking +33%

2015 +

BU PBR Nd-PBR (SGP), H1 2015, new plant 140kt
BU KEL EPDM (CHN), 2015, new plant 160kt
 BU PBR SSBR (BRA) conversion from ESBR (110kt)*
 BU IPG Iron oxide red (CHN), Q1 2016, new plant 25kt




* Expected for the label introduction in Brazil (2016)

A well managed and conservative maturity profile

Long term financing secured


- Diversified financing sources
 - Bonds
 - Private placements
 - Syndicated credit facility
 - Development banks
 - Bilateral bank facilities
- €500 m bond maturity in April 2014 was funded by cash and €200 m EIB facility
- Average €-funding interest rate below 4% after April bond redemption
- All group financings without financial covenants

Liquidity and maturity profile as per March 2014



EIB = European Investment Bank; * €500 m bond repaid in April 2014 and refinanced by cash and draw down of €200 m EIB credit facility

High volatility in raw material prices



- In 2012, raw material prices (mainly butadiene) started a declining trend, with an apparent bottom end of 2013
- Since Q1 2014 raw materials show a slight upward-trend (driven by butadiene)

* Source: LANXESS, average 2008 = 100%

Premium products and technologies for global megatrends

Mobility



Urbanization



Agriculture



Water



Overview exceptional items

[€ m]	Q1 2013		Q1 2014	
	Exceptional	thereof D&A	Exceptional	thereof D&A
Performance Polymers	0	0	9	0
Advanced Intermediates	0	0	1	0
Performance Chemicals	1	0	10	0
Reconciliation	4	0	7	0
Total	5	0	27	0

Abbreviations

Performance Polymers

- BTR Butyl Rubber
- PBR Performance Butadiene Rubbers
- KEL Keltan Elastomers
- HPE High Performance Elastomers
- HPM High Performance Materials

Performance Chemicals

- MPP Material Protection Products
- IPG Inorganic Pigments
- FCC Functional Chemicals
- LEA Leather
- RCH Rhein Chemie
- RUC Rubber Chemicals
- LPT Liquid Purification Technologies

Advanced Intermediates

- All Advanced Industrial Intermediates
- SGO Saltigo

Upcoming events 2014

Active capital market communication

▪ Deutsche Bank 5 th Annual Asia Conference 2014	May 21	Singapore
▪ AGM 2014	May 22	
▪ Oddo Canada Forum	May 27/28	Montreal/Toronto
▪ Equita European Conference	June 3	Milan
▪ Deutsche Bank German, Swiss & Austrian Conference 2014	June 12/13	Berlin
▪ Q2 results 2014	August 6	
▪ Jefferies 10 th Annual Industrials Conference 2014	August 12/13	New York
▪ Capital Markets Day	September 18	Cologne
▪ Berenberg Goldman Sachs German Corporate Conference 2014	September 22-24	Munich
▪ Baader Investment Conference	September 25	Munich
▪ Berenberg Specialty Chemicals & Food Ingredients Conference 2014	Sept 30/Oct 1	London
▪ Q3 results 2014	November 6	
▪ Bank of America Merrill Lynch German Corporate Days 2014	November 18	Singapore
▪ MainFirst Conference	November 18	Paris
▪ HSBC Conference	November 27	Zurich

Contact details Investor Relations

**Oliver
Stratmann**



**Head of
Investor Relations**

Tel. : +49-221 8885 9611
Fax. : +49-214 30 959 49611
Mobile : +49-175 30 49611
Email : Oliver.Stratmann@lanxess.com

**Verena
Kehrenberg**



**Assistant
Investor Relations**

Tel. : +49-221 8885 3851
Fax. : +49-221 8885 4944
Mobile : +49-175 30 23851
Email : Verena.Kehrenberg@lanxess.com



LANXESS IR website

Tanja Satzer



**Private Investors /
AGM**

Tel. : +49-221 8885 3801
Mobile : +49-175 30 43801
Email : Tanja.Satzer@lanxess.com

Ulrike Weihs



**Institutional Investors /
Analysts**

Tel. : +49-221 8885 5458
Mobile : +49-175 30 50458
Email : Ulrike.Weihs@lanxess.com

Dirk Winkels



**Institutional Investors /
Analysts**

Tel. : +49-221 8885 8007
Mobile : +49-175 30 58007
Email : Dirk.Winkels@lanxess.com

Matthias Arnold



**Institutional Investors /
Analysts**

Tel. : +49-221 8885 1287
Mobile : +49-151 74612343
Email : Matthias.Arnold@lanxess.com